NCT05283876

Brief Summary

The aim of this study is to determine the standard tissue levels of SP and its receptor in lesional skin of psoriasis patients in both developing and stationary stages before and after excimer light therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 17, 2022

Completed
21 days until next milestone

Study Start

First participant enrolled

March 10, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 17, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2023

Completed
Last Updated

February 8, 2024

Status Verified

February 1, 2024

Enrollment Period

1.1 years

First QC Date

February 17, 2022

Last Update Submit

February 7, 2024

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (2)

  • Excimer laser efficiency in active and stable psoriasis

    Determine the clinical improvement using Local psoriasis severity index

    through study completion, an average of 6 months

  • Excimer laser efficiency on neurogenic inflammation

    level of affection of the neurogenic inflammation in psoriasis lesions after using Excimer light therapy. Determine substance P and its receptor levels before and after therapy.

    through study completion, an average of 6 months

Study Arms (2)

Active psoriasis

ACTIVE COMPARATOR
Device: Excimer light

Stable psoriasis

ACTIVE COMPARATOR
Device: Excimer light

Interventions

Excimer lightDEVICE

Excimer light sessions

Active psoriasisStable psoriasis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type of Psoriasis: plaque psoriasis.
  • Less than 10% surface area.

You may not qualify if:

  • Erythrodermic psoriasis
  • Pustular psoriasis
  • Topical treatment for psoriasis for the past 2 weeks.
  • Systemic retinoids in the last 2 years.
  • Systemic treatments (including any drugs that affect SP level as Aprepitant) in the last 3 months.
  • Contraindications to excimer light therapy (history of skin malignancy or precancerous conditions like xeroderma pigmentosum or photosensitivity)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kasr Al Ainy Faculty of medicine

Cairo, Egypt

Location

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

February 17, 2022

First Posted

March 17, 2022

Study Start

March 10, 2022

Primary Completion

March 30, 2023

Study Completion

March 30, 2023

Last Updated

February 8, 2024

Record last verified: 2024-02

Locations

EG(1)